anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to lectin-binding proteins and their therapeutic use, inter alia in the field of immunology and oncology. In particular, it relates to the targeting and targeting-enhanced multimerization and activation of galectins. Provided is a galectin-conjugate comprising at least one galectin molecule conjugated to a non-galectin cell targeting means. Exemplary targeting means include targeting means capable of binding to EGP2, a pancarcinoma associated cell surface target antigen, CD antigen, such as CD7 or CD38, or a TNF family member, such as TRAIL-R. The targeting means may comprise an antibody or a functional fragment thereof, preferably a single chain variable antibody fragment (scFv). Also provided is the use of a galectin-conjugate for the treatment of a disease, like cancer or an immune disorder, such as auto-immune disease, allergic disorder, autoimmune encephalomyelitis, arthritis, colitis, hepatitis, asthma, multiple sclerosis, transplant rejection, Graft-versus-host disease (GVHD) and inflammatory bowel disease.
A computerized dispensary management system and method enhances dispensary product management and are supported by a blister pack separation apparatus. The system and method operate according to a computer-implementable application and at least one computer. A scanner system further cooperates with the application and computer for scan-inputting product- and person-identifying machine-readable code information to the application for processing. The person-identifying code is scannable to identify a person and a product regimen for the person. The application provides a series of sequential screenshots based upon basic filler and dispenser screenshots for filler and dispenser side product management, guiding the user through a regimen-filling and administration. The processes are characterized by screenshot re-arrangements occurring thereto as each successive code is scanned. The blister pack separation apparatus operates to simultaneously sever individual blister pack units therefrom, which units are then outfitted with machine-readable code and thus made scannable by the system.
Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.
OBJECTIVES: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment. Their mechanism of action raises the question of possible exacerbation of preexisting multiple sclerosis (MS). The aim of our study was to assess the risk of increased MS activity, defined by the occurrence of a relapse and/or a new MRI lesion, after ICI initiation.
METHODS: This French multicentric study collected retrospective and prospective data on patients with MS treated with ICIs after a cancer diagnosis.
RESULTS: We identified 18 patients with a median age of 48 years. Three of them (17%), all aged 50 years or younger, with a relapsing-remitting course, showed clinical and/or radiologic signs of MS activity 3 to 6 months after ICI initiation. They had stopped disease-modifying treatment (DMT) several months earlier, at the time of cancer diagnosis. Only one had both clinical and MRI activity, with mild severity and complete recovery.
DISCUSSION: Our study suggests that the overall risk of MS activity under ICI is low and could be mainly driven by DMT discontinuation, as in MS in general. Although larger studies are needed for better risk assessment in younger patients with more active disease, ICI should be considered when needed in patients with MS.
The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential antimicrobial activity. In some embodiments, the antimicrobial activity is facilitated via interaction with the lipid bilayer of the parasitic cell form, leading to membrane pore formation and resulting in cell lysis. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites was shown in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2. More specifically, the one or more recombinant antimicrobial peptide effector molecules induce cytotoxicity against infectious agents of the phylum of Apicomplexa.
Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 4. Both administrations will be given through intramuscular route.
1. Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy (see WARNINGS).
  2. Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically.
  3. Periodic (every 6 months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.
  4. Hemoglobin and hematocrit should be checked periodically for polycythemia in patients who are receiving high doses of androgens.
Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
Objective: To investigate the role of RNA m6A methylation in mediating cerebellar dysplasia through analyzing the phenotypes of the mouse cerebella and the expression of several key m6A regulators upon hypobaric hypoxia treatment. Methods: Five-day old C57/BL6 mice were exposed to hypobaric hypoxia for 9 days. The status of mouse cerebellar development was analyzed by comparing the body weights, brain weights and histological features. Immunostaining of cell-type-specific markers was performed to analyze the cerebellar morphology. Real-time PCR, Western blot and immunohistochemical staining were performed to detect the expression of key m6A regulators in the mouse cerebella. Results: Compared with the control, the body weights, brain weights and cerebellar volumes of hypobaric hypoxic mice were significantly reduced (P<0.01). The expression of specific markers in different cells, including NeuN (mature neuron), Calbindin-D28K (Purkinje cell) and GFAP (astrocyte), was decreased in hypobaric hypoxic mouse cerebella (P<0.01), accompanied with disorganized cellular structure. The expression of methyltransferase METTL3 was significantly down-regulated in the cerebella of hypobaric hypoxic mice (P<0.05). Conclusions: Hypobaric hypoxia stimulation causes mouse cerebellar dysplasia, with structural abnormalities in mature granular neurons, Purkinje cells and astrocytes. Expression of METTL3 is decreased in hypobaric hypoxic mice cerebellum compared with that of normobaric normoxic mice, suggesting that its mediated RNA m6A methylation may play an important role in hypobaric hypoxia-induced mouse cerebellar dysplasia.
Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
After an initial run-in period of approximately 1 month (using a chloride-rich fluid strategy), the first study period of 5 months will commence, also comprising a chloride-rich perioperative IV fluid therapy strategy (0.9% saline or 4% albumin). This will include intraoperative fluid and postoperative fluid for the duration of stay in the intensive care unit. This will then be followed by a 1-month transition period before a second period of 5 months will commence where perioperative intravenous fluid therapy will consist of chloride-poor fluids (Lactated Ringer's solution or concentrated 20% albumin). A subsequent 1-month transition period will then be followed by a third period of 5 months characterized by perioperative IV fluid therapy with an alternative combination of chloride-poor solutions (PlasmaLyte® 148 or concentrated 20% albumin). A final 1-month transition period will be followed by a fourth and final period of 5 months characterized by a return to perioperative IV fluid therapy with chloride-rich fluids (0.9% saline or 4% albumin). A final 1-month run-off period using a chloride-rich perioperative fluid strategy will follow prior to study completion.
Provided is an alkynyl-containing ruthenium complex, and also involved are a method for synthesizing the alkynyl-containing ruthenium complex and the use thereof. The alkynyl-containing ruthenium complex is a new type of ruthenium complex, and an alkynyl is introduced into the DPPZ-type ruthenium complex by means of the Sonogashira coupling reaction. The introduced alkynyl is favorable for promoting the transmembrane absorption of drug molecules, improves the probability of drugs entering cells, and can also enhance the pharmaceutical efficacy and lower the toxicity and side effects of the drugs. The alkynyl-containing ruthenium complex provided in the invention has a significant anti-tumor activity, in particular an anti-breast cancer activity, and at the same time, provides a new idea for the design of future anti-tumor drug molecules. The alkynyl-containing ruthenium complex provided in the invention can also be used as a fluorescent probe. In a word, the alkynyl-containing ruthenium complex has broad prospects for use in the field of medicinal chemistry.
The invention discloses a medicine for treatment on bronchitis. The medicine comprises 10g of honeysuckle, 10g of fructus forsythiae, 10g of radix angelicae, 10g of red beans and 10g of herba ephedra. A preparation method of the medicine comprises decocting the medicine through water. The decoction is taken three times every day. The medicine solves the problem that the existing medicine for treatment on bronchitis has large side effects, causes addiction, has long treatment time and a high recurrence rate after drug withdrawal, and cannot thoroughly cure bronchitis. The medicine is suitable for treatment on bronchitis.
Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, dermatology, and can be used for treating psoriasis. For this purpose photochemotherapy with application of photosensibiliser and long-wave ultraviolet radiation is carried out. Additionally pentoxyphillin in amount 200 mg 3 times per day is introduced. ^ EFFECT: method allows to reduce number of procedures, reduce dose of ultraviolet radiation, obtain faster beginning of remission and elongation of its terms, reduce possibility of side effects and complications. ^ 1 tbl, 2 ex
BACKGROUND: In spite of improved survival rates after pediatric liver transplantation, infections remain major contributors to perioperative morbidity and mortality. This study aimed to understand the impact of type and duration of perioperative antibiotic prophylaxis (PAP) on the occurrence of surgical site infections (SSIs).
METHODS: In total, 125 patients who underwent liver transplantation between 2014 and 2020 were retrospectively included. Patients were categorized into two periods based on changes in the standard PAP regimen. Risk factors for SSIs were investigated, including the influence of PAP duration, antibiotic substances used, and abdominal patch placement using multivariable regression models.
RESULTS: SSIs occurred in 23 (19%) of 119 analyzed patients and were not impacted by changes in the PAP regimen. The placement of an abdominal patch was a relevant risk factor for SSIs (odds ratio 3.81; 95% confidence interval [CI] 1.15-12.68). Longer PAP duration reduced the occurrence of SSIs by up to 4.6 percentage points (95% CI 0.0-9.1) per day, with its effect diminishing with longer duration. The choice of antibiotic substances for PAP changed after implementation of the new protocol, with a decline in vancomycin usage from 14% to 3%.
CONCLUSION: The results of this study emphasize the need for evidence-based PAP regimens tailored to the unique needs of pediatric liver transplant recipients. The occurrence of SSIs remains complex and is influenced by various factors beyond the PAP regimen. Multicentric efforts to develop effective prevention strategies against SSIs in this vulnerable population are warranted.
Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Xanthomonas species infect many important crops and cause huge yield loss. These pathogens deliver transcription activator-like (TAL) effectors into the cytoplasm of plant cells. TAL effectors move to host nuclei, directly bind to the promoters of host susceptible genes, and activate their transcription. However, the molecular mechanisms by which TAL effectors induce host transcription remain unclear. We herein demonstrated that TAL effectors interacted with the SIMILAR TO RCD ONE (SRO) family proteins OsSRO1a and OsSRO1b in nuclei. A transactivation assay using rice protoplasts indicated that OsSRO1a and OsSRO1b enhanced the activation of the OsSWEET14 promoter by the TAL effector AvrXa7. The AvrXa7-mediated expression of OsSWEET14 was significantly reduced in ossro1a mutants. However, the overexpression of OsSRO1a increased disease resistance by up-regulating the expression of defense-related genes, such as WRKY62 and PBZ1. This was attributed to OsSRO1a and OsSRO1b also enhancing the transcriptional activity of WRKY45, a direct regulator of WRKY62 expression. Therefore, OsSRO1a and OsSRO1b appear to positively contribute to transcription mediated by bacterial TAL effectors and rice transcription factors.
The invention relates to application of a medicinal composition to preparing a medicament for treating diabetes, which belongs to the field of chemical medicaments. A technical problem to be solved is to provide the application of the medicinal composition to preparing the medicament for treating the diabetes. The medicinal composition is a transdermal absorption preparation. The active ingredient of the medicinal composition is tervalent V inorganic acid salt. Compared with a commercial similar medicament, the medicament has obviously lower cost, so that the financial burden of a patient is reduced; the transdermal absorption preparation is convenient to use and cannot bring pain to the patient; and the patient can take the medicament independently and can stop taking the medicament at any time. Clinical researches show that the medicament has the advantages of no obvious toxic or side effect, obvious curative effect on the diabetes and quick response.
Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
<P>PROBLEM TO BE SOLVED: To provide injectable polysaccharide-cell compositions to be used for a method of correcting defects, more specifically, vesicoureteral reflux, incontinence, or others.  <P>SOLUTION: Slowly polymerizing polysaccharide hydrogels have been demonstrated to be useful as a means of delivering a large number of isolated cells via injection. The gels promote engraftment and provide three-dimensional templates for new cell growth. The resulting tissue is similar in composition and histology to naturally occurring tissue. This method can be used for a variety of reconstructive procedures, including custom molding of cell implants to reconstruct three-dimensional tissue defects as well as general implantation of tissues. Their practical examples indicate the building of muscles and cartilaginous tissue, which is useful for correcting defects such as reflux and incontinence.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A perioperative cardiac arrest is a special form of in-hospital cardiac arrest. It was claimed that perioperative cardiac arrests are under-investigated. The spare existing data suggest incidences of perioperative cardiac arrest to be between 0.5 - 3 per 10.000 for adult patients and 2 - 10 per 10.000 for paediatric patients. Data on circumstances, predictors and outcomes of perioperative cardiac arrest are rare, especially for paediatric patients. Some reports suggest that incidence is negatively associated with a country's higher development. As no Swiss data is available on this topic, this retrospective audit aims to bridge the knowledge gap and finally intends to make clinicians aware of potential risks or contributing factors of survival, which might raise safety for all patients undergoing procedures under anaesthesia.

The investigators will include all patients of all ages with a perioperative cardiac arrest at Bern University Hospital from 1st January 2015 until 31st December 2021 (7 year observational period).
BACKGROUND AND HYPOTHESIS: Nonpsychotic symptoms (depression, anxiety, obsessions, etc.) are frequent in schizophrenia-spectrum disorders and are usually conceptualized as comorbidity or transdiagnostic symptoms. However, in twentieth century foundational psychopathological literature, many nonpsychotic symptoms with specific phenomenology (here termed pseudoneurotic symptoms) were considered relatively typical of schizophrenia. In this prospective study, we investigated potential associations of pseudoneurotic symptoms with diagnostic status, functional outcome as well as psychopathological dimensions of schizophrenia.
STUDY DESIGN: First-admitted patients (N = 121) diagnosed with non-affective psychosis, schizotypal disorder, or other mental illness were examined at initial hospitalization and 5 years later with a comprehensive assessment of psychopathology. Informed by the literature, we constructed scales targeting pseudoneurotic symptoms and other, more general, nonpsychotic symptoms.
STUDY RESULTS: Pseudoneurotic symptoms aggregated in schizophrenia-spectrum groups compared to other mental illnesses and occurred at similar levels at baseline and follow-up. They longitudinally predicted poorer social and occupational functioning in schizophrenia-spectrum patients over a 5-year-period but not transition to schizophrenia-spectrum disorders from other mental illnesses. Finally, the level of pseudoneurotic symptoms correlated with disorder of basic self at both assessments and with positive and negative symptoms at follow-up. The scale targeting general nonpsychotic symptoms did not show this pattern of associations.
CONCLUSIONS: The study supports that a group of nonpsychotic symptoms, ie, pseudoneurotic symptoms, are associated with schizophrenia-spectrum disorders and linked with temporally stable psychopathology, particularly disorder of the basic self. Their prospective association with social and occupational functioning needs replication.
Near-infrared spectroscopy (NIRS) can be employed for the non-invasive real-time evaluation of cerebral oxygen dynamics. A portable wireless NIRS system has been developed to record measurements using a band worn around the head. In this case report, we describe the clinical findings and cerebral oxygen dynamics of a patient who underwent surgery to remove a left temporal subdural haematoma. The patient was a male in his 70s, who fell while riding a bicycle. Following the gradual onset of gait disturbance, the patient was admitted to our hospital for surgery. After surgical removal of the subdural haematoma, the cerebral oxygen dynamics of the left and right frontal cortical hemispheres were monitored using NIRS in the following sequence: supine, bed-up 70°, sitting, standing, and supine, for 3 min each. Measurements were made on postoperative days (PODs) 2, 3, 7, and 10. Clinically, on POD2, the patient had a decreased level of consciousness, requiring assistance in maintaining each posture. On POD10, his level of consciousness improved and he was able to walk for short distances. The cerebral oxygen dynamics on the injured hemispheres showed the most remarkable changes on POD2 which decreased with the passage of time. NIRS may be useful in non-invasive assessment of the recovery of the cerebral circulation after neurosurgical intervention to inform the medical rehabilitation team on the progress in recovery.
This is a prospective multi center, non-randomized, treatment only clinical trial with up to thirty (30) obese with type 2 diabetes subjects. The study is designed to demonstrate that use of the rechargeable TANTALUS II IPG is safe and that it functions as designed.

Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.